Reaction Details |
| Report a problem with these data |
Target | Neprilysin |
---|
Ligand | BDBM298315 |
---|
Substrate/Competitor | n/a |
---|
Meas. Tech. | Enzyme NEP Inhibition Assay |
---|
Ki | 3.55±n/a nM |
---|
Citation | Hughes, AD; Fenster, E; Fleury, M; Gendron, R; Moran, EJ Neprilysin inhibitors US Patent US10123984 Publication Date 11/13/2018 |
---|
More Info.: | Get all data from this article, Assay Method |
---|
|
Neprilysin |
---|
Name: | Neprilysin |
Synonyms: | Atriopeptidase | CALLA | CD_antigen=CD10 | Common acute lymphocytic leukemia antigen | EPN | Enkephalinase | MME | NEP | NEP_HUMAN | Neutral Endopeptidase (NEP) | Neutral endopeptidase | Neutral endopeptidase 24.11 |
Type: | Enzyme |
Mol. Mass.: | 85505.38 |
Organism: | Homo sapiens (Human) |
Description: | P08473 |
Residue: | 750 |
Sequence: | MGKSESQMDITDINTPKPKKKQRWTPLEISLSVLVLLLTIIAVTMIALYATYDDGICKSS
DCIKSAARLIQNMDATTEPCTDFFKYACGGWLKRNVIPETSSRYGNFDILRDELEVVLKD
VLQEPKTEDIVAVQKAKALYRSCINESAIDSRGGEPLLKLLPDIYGWPVATENWEQKYGA
SWTAEKAIAQLNSKYGKKVLINLFVGTDDKNSVNHVIHIDQPRLGLPSRDYYECTGIYKE
ACTAYVDFMISVARLIRQEERLPIDENQLALEMNKVMELEKEIANATAKPEDRNDPMLLY
NKMTLAQIQNNFSLEINGKPFSWLNFTNEIMSTVNISITNEEDVVVYAPEYLTKLKPILT
KYSARDLQNLMSWRFIMDLVSSLSRTYKESRNAFRKALYGTTSETATWRRCANYVNGNME
NAVGRLYVEAAFAGESKHVVEDLIAQIREVFIQTLDDLTWMDAETKKRAEEKALAIKERI
GYPDDIVSNDNKLNNEYLELNYKEDEYFENIIQNLKFSQSKQLKKLREKVDKDEWISGAA
VVNAFYSSGRNQIVFPAGILQPPFFSAQQSNSLNYGGIGMVIGHEITHGFDDNGRNFNKD
GDLVDWWTQQSASNFKEQSQCMVYQYGNFSWDLAGGQHLNGINTLGENIADNGGLGQAYR
AYQNYIKKNGEEKLLPGLDLNHKQLFFLNFAQVWCGTYRPEYAVNSIKTDVHSPGNFRII
GTLQNSAEFSEAFHCRKNSYMNPEKKCRVW
|
|
|
BDBM298315 |
---|
n/a |
---|
Name | BDBM298315 |
Synonyms: | (2S,4R)-5-(3'-Fluorobiphenyl-4-yl)-2-hydroxymethyl-2-methyl-4-(oxalylamino)pentanoic Acid | US10123984, Example 10 | US10744104, Example 10 | US11547687, Example 10 | US11547687, Example 11-1 | US20230285340, Example 10 |
Type | Small organic molecule |
Emp. Form. | C21H22FNO6 |
Mol. Mass. | 403.4009 |
SMILES | C[C@@](CO)(C[C@@H](Cc1ccc(cc1)-c1cccc(F)c1)NC(=O)C(O)=O)C(O)=O |r| |
Structure |
|